Neuropathic Pain - Treatment of neuropathic pain is a clinical challenge, as the pathogenesis is very complicated. The pathology of neuropathic pain involves the entire nervous systems, including the peripheral nerve, dorsal root ganglion, spinal cord, and brain. The main idea of applying stem cells to neuropathic pain is based on the ability of stem cells to release neurotrophic factors, along with providing a cellular source for replacing the injured neural cells, which make them ideal candidates for modulating and possibly reversing intractable neuropathic pain.
Stem Cell | Stem Cell, PRP, Acupuncture in Queens & Long Island, New York
Although many countries including the USA, China, Italy, UK, France, Spain, Germany, Turkey, Iran, Brazil, and Jordon have proposed stem cell use for COVID‐19 patients, only a limited number of stem cell‐based studies are available currently to deduce solid limitations or potential of such therapy for COVID‐19. A study recently conducted in Beijing's YouAn Hospital, China, from January 23, 2020 to February 16, 2020 suggests a possible role of MSCs administration in COVID‐19 treatment (Leng et al., 2020).
Most COVID‐19 patients do not develop any major clinical symptoms during the early stages of infection. Common symptoms include mild or high temperature, cough, sore throat, muscle distress, and body pain. In a few patients, shortness of breath can lead to a sudden deterioration in the health of the patient during the later stages of the disease. In severe cases, immune system dysfunction is the major cause of death in patients as infection stimulates inflammatory cytokines that result in the respiratory system being overwhelmed by a storm of inflammatory cytokines such as interleukin 2 (IL‐2), IL‐6, granulocyte colony-stimulating factor, IP10, MCP1, MIP1A, and tumor necrosis factor.
Stem cells are unspecialized cells in the body that have the potential to make more stem cells as well as differentiate into specialized cells of the body if appropriate signals are given in vitro or in vivo. Embryonic stem cells (ESCs) can be isolated from the inner cell mass of 5–8 days old embryos and possess high regenerative potential. However, the clinical use of ESCs is restricted due to a number of religious, ethical, and legal controversies. Adult stem cells can be isolated from neonatal sources (such as cord blood, cord tissue, placenta, and menstrual blood) as well as from adult tissues (such as bone marrow, adipose tissue, dental pulp, and peripheral blood) are used for these purposes.
1,200 are already fully recovered from the effects of the virus. The Abu Dhabi Stem Cell Centre (ADSCC) has now treated more than 2000 patients suffering from COVID-19, with 1200 already fully recovered from the effects of the virus. ADSCC announced today that it had succeeded in ramping up the number of treatments from the 73 in the initial clinical trial. The large increase was as a result of a major effort by staff at the center to treat as many people as possible following the UAE Government’s decision to make it available free of charge to all moderate-to-high risk COVID-19 patients in the country.
Researchers announce the first patient has been dosed in a trial testing remestemcel-L, a stem cell therapy, in severe COVID-19 patients on ventilators. Testing of an experimental COVID-19 stem cell therapy has begun in the US. The therapy has been developed to treat hospitalized COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators. A total of 300 are expected to be recruited into the randomized, placebo-controlled trial. The trial, in which patients will either receive the drug remestemcel-L or a placebo in addition to the recommended standard of care, is being conducted by the University of Maryland School of Medicine (UMSOM) researchers at the University of Maryland Medical Center (UMMC) and additional sites across the US. The first patient was treated at UMMC.
100 million adults in the United States - The majority of chronic pain in the United States is the result of a musculoskeletal injury stemming from trauma, disease, or illness. It is estimated that more than 100 million adults in the United States deal with some form of back pain throughout the year. And for many of these individuals, their back pain gradually goes from being acute to chronic.
Chronic pain is like a thief that can deprive your life of its joy. It can leave you with a terrible sense of hopelessness. Chronic pain sufferers find themselves receding into a routine that is dominated by a constant struggle to focus on life in spite of the pain. Everything else falls to the wayside. The things that they love to do, the things that give their life joy and meaning, become impossible. Depression quickly sets in, and a person who is battling chronic pain can lose hope that their life will ever return to what it was before. If you are currently battling chronic pain, we empathize with what you are going through.
Researchers urge measured optimism about new studies on stem cell treatments for heart issues, rotator cuff injuries, and hair loss. Stem cells have been touted as treatments for everything from hair loss to heart disease. But are those claims scientifically sound? Research on the technology continues to look promising, but many of its human applications are still preliminary and their effectiveness anecdotal. Samumed, a $12 billion biotech start-up based in San Diego, profiled in Business Insider, exemplifies both sides of the coin.
Using sheep, whose knees are similar to human knees, researchers got the meniscus to regrow itself by implanting a biodegradable plastic device to lure stem cells and help them grow. Every year about 1 million people have surgery to repair a tear in the meniscus of their knee, according to the American Academy of Orthopedic Surgeons. It’s an injury that can’t be fully fixed since cartilage doesn’t repair itself very well. Even patients who have surgery often go on to develop arthritis. Some eventually need a knee replacement.
Love this Post? Spread the World